https://doi.org/10.1172/JCI169297 Freja Herborg & team explore the behavioral consequences and dopaminergic dysfunction that arise from patient-derived mutations in the dopamine transporter associated with parkinsonism and co-morbid neuropsychiatric disease, establishing a new mouse disease model.
The images show striatal slices with decreased immunolabeling intensity of both DR1 and DR2 in DAT-I312F/D421N+/+ mice compared with WT mice.
1Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
2CNS Research Group, Department of Pharmacology and Physiology, Department of Neurosciences, Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada.
3Centre for Neuroscience and Stereology, Copenhagen University Hospital Bispebjerg-Frederiksberg, Copenhagen, Denmark.